Neko Health raises $700M to open U.S. body-scan clinic

Neko Health said it has raised $700 million in a Series C round led by Lightspeed Venture Partners and co-led by O.G. Venture Partners to open clinics in the United States, starting with New York. The company named investors including Atomico, General Catalyst, Lakestar, Liberty City Ventures, Positive Sum and BDT & MSD. The round included individual backers from previous rounds and brings disclosed funding since 2023 to more than $1 billion.

The Neko Health Scan is a roughly 60-minute, non-invasive and radiation-free assessment that combines full-body imaging, on-site blood tests, proprietary sensors and clinician review. The service captures more than 2,000 high-resolution skin images, performs an electrocardiogram, arterial measurements and body-composition analysis, and screens for signs linked to skin cancer, cardiovascular disease, diabetes and metabolic syndrome. Results are reviewed in person, and clinicians provide referrals or follow-up when recommended.

Two of Neko’s devices received FDA 510(k) clearance in May 2026. Derma-2 is cleared as an adjunctive telethermographic system and Spectrum-2 as a tissue-saturation oximeter for cardiovascular measurements. The clearances apply to those specific devices and uses, not to the complete Neko Health Scan as a single FDA-approved screening service.

The company currently operates eight clinics across the UK and Sweden, including four sites in London and locations in Stockholm, Manchester and Birmingham. Neko charges £299 for a scan in the UK and 2,750 kronor in Sweden. The firm reported completing 100,000 scans since launching publicly in 2023, and more than 350,000 people have registered for scans or joined waitlists. About 75% of customers book and prepay for a follow-up scan at the end of their appointment.

Neko has updated its Derma, Echo and Spectrum devices and added body-composition measurements and clinician review of wearable-device data across clinics. The company said the newer equipment captures more data and automates parts of the scanning process. A Covent Garden clinic was built to support tens of thousands of scans a year; Neko has not released staffing or capacity figures for planned U.S. sites.

The company describes its U.S. clinics as preventive health and wellness providers rather than full-service medical practices and advises customers to continue seeing their regular clinicians for diagnosis and treatment. Neko’s U.S. clinics do not currently participate in health insurance plans and most services are expected to be paid directly by customers; the company has not announced U.S. pricing or whether employers or insurers will subsidize access.

Public materials available for review do not include a completed peer-reviewed study validating the full multimodal screening service. A registered clinical trial is ongoing to evaluate Neko’s skin-imaging technology for screening and diagnostic support. The company has not published statistics on false-positive rates, how many customers undergo additional procedures after a scan, or detailed real-world performance figures for the algorithms that combine or interpret scan data.

Neko reported an internal analysis of 1,469 customers who had a second scan about a year after their first and said that group recorded improvements in blood pressure, cholesterol and blood sugar. The company acknowledged the analysis was not a controlled study and cannot establish causation because customers could have started treatment or changed behavior between appointments.

Founded in 2018 by Spotify co-founder Daniel Ek and chief executive Hjalmar Nilsonne, Neko has expanded its clinic network since launching publicly in 2023. The company said part of the new funding will be used for research and development of preventive screening technology and to scale its clinic network and equipment deployments. David Ofer of O.G. Venture Partners is expected to join Neko’s board, subject to regulatory approval.